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We have shown previously that angioten~in-ll (A-II) controls proto-oncogene (c.Jbs, juJ~-B and e-ju,) mRNA accumulation i bovine adrenal 
fa.~eieulata cells (BAC). Since BAC contain both subtypes tAT-1 and AT-2)of the A-Ii receptor, we have investigated which sublype was involved 
in the effect of A-II on proto.oncogene mRNA by using a selective antagonist for AT-I (DUP 753) and for AT-2 (CGP 42112A), DUI a 753, bat 
n~ CGP 42112A, inhibited the stimulatory efi'ect of A-il on proto.oncogene mRNA, with IDeas of 4 × 10 -~ M, 7 × 10 -* M and 2 × 10 -~ M for 
c-Jbs, jtm.B and e-jttn, respectively. Neither of the two antagonists by themselve~ had a direct effect on proto-oncogene mRNA. As the A-ll AT-I 
receptors are coupled to the phospholipase C system in BAC, we haw investigated whether the A-ll effects on the proto-oncogenes were mediated 
~y protein kina,~e C (PKC) or by Ca ~-" calmodulin. First, activation of PKC by the phorbol ester, PMA, increased the level of the three proto~nco- 
gene mRNAs, whereas calcium ionophore had no effect. Second, staurosparine, a specific inhibitor of PKC, redtzeed the ztimulatory action of A-I! 
on proto.oneogene mR NA by 80-.90%, whereas trilluoroperazine, aninhibitor of ealmadulin, had no significant effect. These results demonstrate 
that the effects of A-I! on proto-oneo~ene mRNA are mediated by ATI receptor subtylx:S, mainly through activation of the PKC pathway. 
Proto-oncogene; c.Jbs; c-jutt; jt#l.B; Adrenal; Angiotensin-ll 
1. INTRODUCTION 
Angiotensin-ll (A-II) is a pleiotropic hormone which 
regulates a variety of responses inchtding adrenal and 
renal function, blood pressure~ pituitary function and 
fluid homeostasis [1]. In addition, A-II ha~ multiple 
actions in the central nervous system [2]. A-II receptors 
are widely distributed throughout many tissues, but 
pharmacological and functional studies have suggested 
the existence of A-II receptor subtypes [1-3]. Recently 
binding studies with new A-I! antagonists have revealed 
the existence of two distinct receptor subtypes, termed 
AT-I and AT-2 [4,5], the first of which has recently been 
cloned [6J]. 
Bovine adrenal faseiculata cells (BAC) contain both 
subtypes of A-II receptors [8], but all the acute effects 
of A-11 on these cells are mediated by AT-1 receptors~ 
which, as in other cell systems, are coupled to phospho- 
inositide breakdown. Recently, it has been shown that 
A-II increases the levels of three nuclear proto-o~co- 
gene mRNA levels in BAC 1"9]. However, the A-II recep- 
tor subtype involved in this effect of the hormone on 
early gene expression is unknown. Therefore in the pres- 
ent study we have investi.ga~:ed which subtype of A-II 
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receptors is involved in these effects of A-II on early 
gene expression. 
2. MATERIALS AND METHODS 
Synthetic :mgi0tensin-ll iA°ll) was obtained from Bachem (Uubcn- 
dorl; Switzerland); Staurosporine from iaoehringer (Mannheim. Ger- 
many,; insulin, transfcirim 4,~.phcrbot 12-myris:ate-13-aeet:te 
(PMA), ionophore A23187, trifluo~ zpcrazine dihydrochloride (TFP) 
from Sigma CheJnie~ls Co. (St. Louis, MO); Ham's F-12 m~iam and 
Dnibeceo's modified Eagle's m~inm (DMEM) in powder form, nys- 
turin, penicillin/streptomycin, trypsin/EDTA, fetal calf serum from 
Gibeo (Paris. France), Motlse e.jun and jun-B ¢DNAs were kindly 
provided by Dr. 1. Venna (Sulk Institute. San Diego, CA) [5] and Dr. 
D. Nathans (Johns Hopkins, Baltimore. MD) [6], respectively. Rat 
glyccraldehyde-3-phosphate-dehydrogenase (GAPDI'i) eDNA was a 
gift from Dr. J.M. Blanchard (Mont~llier, Fran~.'¢) [71. c-f as was 
purchased from Oneor (Gaither~burg, MD). The non-pcptide antago- 
nist DUP753, ~v~ts provided by Dr. R.D. Smith (Dupont Merck Phar- 
maceutical Co., Wilmington. DE) and the peptide antagonist CGP 
,12112A was a gift from Dr. M. De Gasl~tro {Ciba-Geie-y, Basel. 
Switzerland). 
2.1. Cell isohuh~tt and culture 
BAC were prepar~ by sequential treatment of adrenal cortical 
flices with trypsin (0.19%) as previously der~eribcd [8,9]. The o:lls were 
ctdtured in a chemically defined medium, Ham's FI~DMEM {1:1), 
containin~ tranfferrin (10#~ml), insulin (5/~ffml), vitamin C ( 10 -'~ M) 
,And .L.n!ihintie,~ The experiments were carried out on ceils ¢ullttred for 
three &tys. The A-il antagonists and the inhibitors of protein kina~e 
C and ealmodulin were added 15 rain before addition of the stimula- 
tory agents, and continued for I h. 
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2.2. Cortisol determination and measl,'ement of the acctttnul~ttion f"
[~H finos~'tol phosphates 
Cortisol and ['~H]inositol phosphate accumulation were carried out 
a~ previously described [8,9]. 
2.3. RN,,I isolation aml Northertt or sh~t blot atta/ysis 
For each treatment, the culture medium was r~moved fi'om 25 era-" 
flasks, ¢ell~ were harvested in guanidine thioeyanate, and total RNA 
was extracted according to the method of Chomczynski and Saeebi 
[10]. For Northern blot analysis, total cytoplasmic RNA (10 pg) was 
subjected to electrophoresis through 1% agarose gels and translerred 
under vacuum to Hybond.N nylon membrane (Amersham, UK). For 
each munpl¢ analyzed by slot blot, increasing amounts of total cyto- 
plasmic RNA (1,2, 4, ,'md 6~+g) were transferred directly to Hybond-N 
nylon membrane asing +t multiwell filtration manifold (BRL). Mem- 
branes with bound RNA were irradiated for 2 mill by ultraviolet light 
and were baked .'tt 80°C to cross-link the RNA to the filters. Hybrid- 
ization with complementary DNA "~P-labdlmd probes and the analyais 
of blots were curried out as previously described [9]. 
Analysis of each Northern blot was realized in duplicate. The den- 
sitometric values Ibr the proto-on¢ogene mRNA levels were normal- 
iz~ to those for GAPDH to control for quantity of RNA transferred 
to the blot. 
2.4. Statistics 
Data are reported as tile mean __. S.E.M. for a minimunl of three 
different cell preparations. Statistical significance was determined with 
Studenl's t-test. The null hypothesis was rejected when P < 0,05 was 
obtained. 
3. RESULTS AND DISCUSSION 
In the first series o f  exper iments ,  the effects of  A - I I ,  
either a lone or together  with its antagonists ,  on  inositol  
phosphate  accumulat ion ,  cort isol product ion and  
proto -oncogene mRNA were studied (Table I). Ne i ther  
the AT . I  antagonist ,  DUP 753, nor  the AT-2  antago-  
nist, CGP 42112A, had any agonist ic  act ion,  whereas 
A - I I  (Sar~,Thr~), an antagon is t  o f  A- I I ,  had a small  
s t imulatory  effect on cort isol product ion.  As  expected,  
this peptide a lmost  complete ly  b locked the s t imulatory  
effects o f  A - l I  on BAC.  DUP 753 at 10 -~ M,  a conc :n -  
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Fi~. 1. Effects of A-|I and/or its antagonists on proto-oncogene 
mRNA levels. Representative Northern blots, l, Control; 2, A-11 (10 -~ 
M); 3, A-II + DUP 753 (10 -7 M);4, A-II + DUP 753 (10 -~ M); 5, A.II 
+ DUP 753 (10 -~ M): 6, A-il + DUP 753 (10 -'~ M); 7, A-Ii + CGP 
(5 × 10 -a M); 8, A-ll (Sar~,Thr ~) (10 -7 M); 9, A-II + A-II (Sart,Thr ~) 
(10 -~ M), 
t rat ion which occupies most  o f  the AT- I  receptors,  
b locked the effects of  A - I I  on inositol  phosphate  accu- 
mulat ion ,  cort isol  p roduct ion  and jan-B,  c-fos and c~/un 
mRNA levels by 80-90%.  In contrast ,  CGP 42112A at 
5 × 10 -~ M, a concent ra t ion  at which this compound 
occupied most  o f  the AT-2  receptors  [8], had no effect 
on the s t imu la tory  act ions o f  A- I I .  These  results, there- 
fore, suggest that  the effects o f  A - l [  on proto -oncogene 
mRNA were med ia ted  by the AT-1 receptor  subtype 
(Table  1 and Fig. 1). 
The  inhib i tory effects o f  DUP 753 on A- l I - induced 
proto -oncogene mRNA levels were dose-dependent ,  
with IDms o f  3.3 + 0.8 × 10 -7 M, 7.3 + 1.8 x 10 -7 M and 
2 "+ 0.4 x 10 -~ M (n = 4) for  c-los, jun-B and c-],tn, 
respectively (Fig. l). Due  to the large var iat ion in val- 
Table I 
Effects of A-II and/or its antagonists on BAC 
Fold stimulation over control without A-II 
- A . I I  + A-I I  10 -~ M 
Control A-II (Sart,Thr ~) DUP 753 CGP 42112A Control A-II ($ar~,Thr ~) DUP 753 CGP 42112A 
(10 -~ M) (10 -~ M) (5 × 10 -a M) (10 -~ M) (10 -~ M) (5 × 10-" M) 
insP 1 1,1 _+ 0,2 1,0 +_. 0.1 0,7 __: 0.I 7 + 0.4 ~ 1.2 + 0,2 ~ 1.3 + 0.1 t+ 6,4 ± 0.3" 
Cortisol 1 2,4 _ 0.3" 1.2 ± 0,4 0,7 ± 0.1 117 ± l l" 2.5 ± 0,4 t~ 12 + 1 "'b 118 ± 13" 
jtm.B l 1.1 ±0.3 1.3±0.2 0.8~0.05 24 + 2" 1.3+0.4 b 5 ±2 ~ 31 __. 7 ~ 
c-jtu; I 1.2 +_ 0.2 IA + 0.1 1.5 __. 0.2 4.1 ± 0.5" 1.4 ± 0.3 ~ 0,9 ~ 0.2 b 5.4 :J: 1.2" 
e.jbs 1 1.5 __.0.1 1.0 + 0.3 1.2 ± 0.2 14 ± 2 ~ 2 ± 0.3 ~' 3.4_ 1.3 h 13 '.= 3" 
On the third day of culture, cells were treat~ with tile irtdicatcd eff~tor. The antasonists were added 15 rnin before A-II, laositol phosphate (lnsP) 
accumulation was measured 30 min after addition of A-II, wbereas cortisol production and proto.oncogene mRNA accumulation were evaluated 
30 rain later, The results are given as mean ~ S,E,M, of at least three different ¢¢11 preparations, The proto.nneogen," mRNAs were evaluated by 
Northern blot analysis. 
"P < 0.05 vs, control without A.il of tile same row. 
Sp < 0.01 vs, A-ll alone of tile same row. 
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ucs, the ID~0s for c-fox and flm-B are not statistically 
different, but that of c-/un was higher. However, all 
these values are in range of the ID~ to inhibit [:"I]A-II 
binding (6 +_. 1.4 × 10 -7 M) and the ICs0 to inhibit 
A-II-indueed inositol phosphate accumulation (1.7 + 1 
× 10 -6 M) [8]. 
Activation of the two branches of the phosphoinosi- 
tide pathway, protein kinase C and calmodulin, are re- 
quired for full expression of the steroido,~enic effects of 
A-II on both adrenal glomerulosa cells [11] and BAC 
[12] (Table 1I). We have investigated whether these two 
branches are al~o required to induce the expression of 
proto- oncogenes in BAC. Two approaches were used. 
In the first, we compared the stimulatory effects of A-II 
on proto-oncogene mRNA, levels with those induced by 
activators of protein kinase C (phc, rbol ester PMA) or 
Ca:+/calmodulin (calcium ionophom A23187) or both 
(Table II), PMA alone was able to increase both cortisol 
secretion and proto-oncogene mRNA levels, but its ef- 
t'ects were significantly lower than those induced by 
A-[I. In contrast+ A23187, either alone or together with 
PMA+ had no stimulatory action on proto-oncogen¢ 
mR.NAs. 
In the second approach, we used the specific inhib- 
itors of each branch of the phosphoinositide pathway. 
Staurosporine has been shown to be a potent inhibitor 
of protein kinase C in many cell systems [13]+ including 
BAC [14], whereas trifluoroperazine (TFP) is an inhibi- 
tor of ealmodulin in several cell types [15], including 
BAC [14]. As shown in Table Ili, staurosporine inhib- 
ited the stimulatory action of A-11 on proto-oncogene 
mRNA levels by 80-90%. TFP produced a small, al- 
though not statistically significant, inhibition of the ef- 
fects of A-ll on proto-oncogene expression. A combina- 
tion of both inhibitors had only small effects on jun-B 
mRNA when compared to the effect of staurosporine. 
The low inhibitory action of TFP might be due to its 
ability to slightly inhibit PKC at high concentrations 
[15]. Thus, both sets of experimental pproaches indi- 
cate that the stimulatory action of A-II on proto-onco- 




0 10 '? I0  "(~ 10 ,5 Ig , l  
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Fig, 2, Inhibitory ell'eels of inereaming concentrations of DUP 753 on 
the A.II-indueed increase in e-fos (zx), e.jun (~) andjun.B (e) mRNA 
levels. The results arc the mean ± S.E.M. of three different expcri- 
f r l c l l t t ; .  
gene mRNA levels is mainly mediated through activa- 
tion of PKC. 
Although the acute effects of A-II on both steroid 
production and proto-oncogene mRNA levels are medi- 
ated by the AT-1 receptor subtype, the effects are unre- 
lated since inhibitors of protein synthesis block the stim- 
ulation of steroidogenesis by A-II but potentiate its ef- 
fects on proto-oneogene mRNA [9]. In addition to these 
acute effects, A-11 has a long-term inhibitory effect on 
the differentiated functions of BAC by inducing a 
down-regulation f its own receptors [16,17]. This is+ in 
part, related to a decrease in the mRNA for the AT-I 
receptor subtype (R. Ouali and J.M. Suez, unpublished 
results), and a decrease in the expression of genes encod- 
ing for steroidogenic enzymes [17-19]. How this long. 
term action of A-II is related to its effects on proto- 
oncogene xpression is unknown. However, ACTH, 
which also increases c-Jbs and jun-B but not c-jun 
mRNA levels, has a long-term positive effect on the 
differentiated functions of BAC [17,20,21]. Since e-jun 
Table 1I 
Comparative ffects of A.IL, the phorbol ester. PMA, and the calcium ionophore. A23187, on cortisol production and proto-oneosene mRNA 
leveh in BAC 
Fold stimulation over control 
Cortisol jun-B c.jun c.fos 
A-II (10 -~ M) 84 _+ 12 17.4 ± 1,1 5.0 ± 0,8 16.9 -t- 1.7 
PMA (10 "~ M) 28 +_. 4" I!.l +_ 0.9 ~ 3.8 __. !.2 5.8 _ 2.2" 
A23187 (10 -~ M) 18 + 3" 0,7 +- 0,1" 0,9 __ 0.05" i.7 ± 1.0 ~ 
PMA ÷ ionophore 5! ± 4 t' 10.2 _+ 2,0 ~ 2,9 _ 0.6 6.5 ± I.P' 
" ~ . . . .  + , . i e  l+,4m|..++~.,, , ,  + ,,,~+,,,.w.O+,.+. • . .+  C=ii+, o£t tlm third d.y uf cm ue+ ~+cr+ incubate.d with '" ...a .°, .~ + , + Afteri h the cortisol in fl'le medium was measured and total RNA 
was extracted. The levels of proto-oncosene mRNA were detennim.'d by ~lot blot analysis as indicated it,Materials and Methods. The result5 are 
given as th~ mean :I: S.E.M. of 3-10 e~periment.'~. 
"P  < 0,05 compared to A.i l  alo,e, 
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Table Ill 
Inhibition of A-ll-induced proto.oneogene expression by protein ki. 
nas~ C and/or calmodul[n inhibitor 
% of A-[I alone 
jun-B c-ju~l e.:q~s 
A-II (10 -~ M) 100 100 100 
Control 5,7 --. 2,1 24.0 ± 6.5 10,0 ":" 2.5 
A-II + stattrosporine 
(10 -~M) 23.0± l.l ~ 24.0 ~ 3.0 ~ 15.0± 4.0" 
A-II • TFP (10 -s M) 86,0 + 15 76,0 +__ 8.3 80,0 ± .]3,5 
A-II + ~taurmporine + 
TFP 10,0 + 1.5 ~~ 19,5 ± 0.5 ~ 18,0 .0- 2,0 ~ 
on the third day of culture, BAC were incubated with the indicated 
effector~ for I h. The proto..oncogene mRNA~ were quantified by ~lot 
blot analysis as described in Materials and Methods, The results are 
glvcn us the mean ± S.E,M, of 3-6 e:~perinaents. 
"P < 0.01 compared te A-I! alone. 
bp < 0,05 compared to A-il + staurosporine, 
' P < 0.05 compared to A.II + TFP. 
and jun-B  have d i f ferent  act ivat ion  domains  and  di f fer  
in their  biological  p roper t ies  in several cell types [22,23], 
it has been postu la ted  that  the homodimer~ c.jun, and/or  
the heterod imer ,  c-jun/c.foso may be responsib le  for  the 
long- term negat ive effects o f  A..ll on d i f ferent iated 
funct ion of  BAC.  Fur ther  studies, in par t i cu lar  tho~e 
using t ransfect ion exper iments  with normal  or  mutated  
proto -oncogenes ,  are  requi red to detemaine the role o f  
early p ro to -oncogene xpress ion on the long- term plei- 
o t rop ic  ef fects o f  : ,4{  oft eel,( di, fferetxtiat/.ort. 
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